Allogene Therapeutics, Inc (ALLO)

Etorro trading 970x250
Allogene Therapeutics, Inc (ALLO) Logo

About Allogene Therapeutics, Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was founded in 2017 and is headquartered in South San Francisco, California. Address: 210 East Grand Avenue, South San Francisco, CA, United States, 94080

Allogene Therapeutics, Inc News and around…

Latest news about Allogene Therapeutics, Inc (ALLO) common stock and company :

Is Allogene Therapeutics (NASDAQ:ALLO) Using Too Much Debt?
12 Aug, 2022 Yahoo! Finance

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

What 5 Analyst Ratings Have To Say About Allogene Therapeutics
10 Aug, 2022 FinancialContent

Over the past 3 months, 5 analysts have published their opinion on Allogene Therapeutics (NASDAQ:ALLO) stock. These analysts ...

Allogene (ALLO) Q1 Earnings Beat, Pipeline Progressing Well
10 Aug, 2022 Yahoo! Finance

Allogene's (ALLO) second-quarter earnings beat estimates. ALLO is on track to initiate a pivotal phase II study on ALLO-501A in large B cell lymphoma in the coming weeks.

Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2022
10 Aug, 2022 FinancialContent

Upgrades According to Stifel, the prior rating for V2X Inc (NYSE:VVX) was changed from Hold to Buy. The current stock ...

Allogene Therapeutics (ALLO) Reports Q2 Loss, Tops Revenue Estimates
09 Aug, 2022 Yahoo! Finance

Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 14.75% and 7.50%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Allogene Therapeutics: Q2 Earnings Insights
09 Aug, 2022 FinancialContent

Allogene Therapeutics (NASDAQ:ALLO) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's ...

Allogene Therapeutics Reports Second Quarter 2022 Financial Results
09 Aug, 2022 Yahoo! Finance

U.S. FDA Clearance on Potential Pivotal Phase 2 Trial of ALLO-501A Anticipated in Coming Weeks Expected to be the Industry’s First Allogeneic CAR T Phase 2 Pivotal TrialClearance to Cover ALPHA2 Protocol and Chemistry Manufacturing and Controls (CMC) for Use of ALLO-501A Manufactured from Cell Forge 1 (CF1)CF1 is Projected to Support the Manufacture of ~20,000 Doses of AlloCAR T™ Products Annually at Scale CF1 Earned a LEED® Interior Design and Construction Gold Designation from the U.S Green Bu

Allogene Therapeutics Stock Earns RS Rating Upgrade; Hits Key Threshold
03 Aug, 2022 FinancialContent

A Relative Strength Rating upgrade for Allogene Thera shows improving technical performance.

Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences
03 Aug, 2022 Yahoo! Finance

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that management plans to participate in three upcoming investor conferences. 42nd Annual Canaccord Genuity Growth ConferenceThursday, August 11, 2022Noon PT/3:00PM ET H.C. Wainwright 24th Annual Global Investment ConferenceMonday, September 12, 2022Presenta

Analysts Expect RXL Will Reach $103
02 Aug, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the ProShares Ultra Health Care ETF (RXL), we found that the implied analyst target price for the ETF based upon its underlying holdings is $103.49 per unit.

Why Beam Therapeutics Stock Dipped Today
01 Aug, 2022 FinancialContent

A clinical hold is weighing on the biotech's shares today.

Allogene Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022
27 Jul, 2022 Yahoo! Finance

Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ETSOUTH SAN FRANCISCO, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will report second quarter 2022 financial results on Tuesday, August 9, 2022, after the close of the market. The announcement will be followed by a live audio webcast and conference call

Allogene Therapeutics' Charts Suggests a Rally Ahead
25 Jul, 2022 Yahoo! Finance

According to its website, Allogene Therapeutics is developing allogeneic chimeric antigen receptor T cell products to find the next immunologic breakthrough in cancer -- cutting edge stuff and way above my pay grade.

Buy These 2 Stocks Before They Jump Over 40%, Says Goldman Sachs
24 Jul, 2022 Yahoo! Finance

Markets turned down in the first six months of this year, but they’ve trended up in July. Despite Friday’s pullback, the monthly gains are solid, almost 5% on the S&P 500 and 7.5% on the NASDAQ, marking a turnaround from the long drop we saw earlier. The question investors have is, is this turnaround real, or just a temporary gain in a larger bearish trend. That remains to be seen, but either way, even if the market reverts to its bearish trend, there will be opportunities for investors - findin

Beyond Meat, Canoo, Veru And More: 12 Short Squeeze Candidates To Watch
20 Jul, 2022 FinancialContent

One of the most powerful tradable market events is a short squeeze, so traders are always on the lookout for the next short squeeze ...

Interesting ALLO Put And Call Options For September 16th
18 Jul, 2022 FinancialContent

Investors in Allogene Therapeutics Inc (ALLO) saw new options begin trading this week, for the September 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ALLO options chain for the new September 16th contracts and identified one put and one call contract of particular interest.

Allogene Therapeutics (ALLO) Shares Cross Above 200 DMA
15 Jul, 2022 FinancialContent

In trading on Friday, shares of Allogene Therapeutics Inc (ALLO) crossed above their 200 day moving average of $12.54, changing hands as high as $14.06 per share. Allogene Therapeutics Inc shares are currently trading up about 4% on the day..

Benzinga's Top Ratings Upgrades, Downgrades For July 15, 2022
15 Jul, 2022 FinancialContent

Upgrades B of A Securities upgraded the previous rating for TechnipFMC PLC (NYSE:FTI) from Neutral to Buy. For the first ...

12 Health Care Stocks Moving In Friday's Pre-Market Session
15 Jul, 2022 FinancialContent

Gainers NexImmune (NASDAQ:NEXI) shares moved upwards by 29.9% to $1.91 during Friday's pre-market session. The ...

Allogene Therapeutics Appoints Scientific Pioneer Stephen Mayo to its Board of Directors
12 Jul, 2022 Yahoo! Finance

SOUTH SAN FRANCISCO, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced the appointment of Stephen L. Mayo, Ph.D., a world renowned expert in computational protein design, to the company’s Board of Directors. “We are privileged to have Dr. Mayo join our Board of Directors,” said David Chang, M.D., Ph.D., President, CEO and Co-F

89 Biggest Movers From Friday
21 Jun, 2022 FinancialContent

Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 ...

We're Not Very Worried About Allogene Therapeutics' (NASDAQ:ALLO) Cash Burn Rate
20 Jun, 2022 Yahoo! Finance

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Allogene Therapeutics (ALLO) Moves 16.4% Higher: Will This Strength Last?
20 Jun, 2022 Yahoo! Finance

Allogene Therapeutics (ALLO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to ALLO-501A for Large B Cell Lymphoma
08 Jun, 2022 Yahoo! Finance

RMAT Designation Follows Positive Data from ALLO-501A ALPHA2 Trial in Heavily Pretreated Patients with Relapsed or Refractory Large B cell Lymphoma (LBCL) Data Presented at the American Society of Hematology (ASH) 2021 Annual Meeting Demonstrated AlloCAR T™ Could be Safe and Effective in Producing Durable ResponsesIn the ALPHA Trials with ALLO-501 and ALLO-501A, Treatment was Initiated Approximately 2 Days from Enrollment, Eliminating Any Need for Bridging Therapy Company Intends to Initiate a P

Why Is Allogene Therapeutics (ALLO) Down 14.9% Since Last Earnings Report?
03 Jun, 2022 Yahoo! Finance

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2022
03 Jun, 2022 FinancialContent

Upgrades Keefe, Bruyette & Woods upgraded the previous rating for Regions Financial Corp (NYSE:RF) from Underperform ...

What 4 Analyst Ratings Have To Say About Allogene Therapeutics
03 Jun, 2022 FinancialContent

Analysts have provided the following ratings for Allogene Therapeutics (NASDAQ:ALLO) within the last quarter: ...

Peek Under The Hood: IYY Has 33% Upside
20 May, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Dow Jones US.

Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Improved Anti-Tumor Activity of Donor-Derived Allogeneic CAR T Cells at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
19 May, 2022 Yahoo! Finance

Cells Derived from Healthy, Younger Donors were More Abundant with Greater Fitness and Cancer Killing Potential Than Cells Derived from Patients with CancerFindings Underscore Potential of Allogeneic CAR T Products to Improve Patient Outcomes SOUTH SAN FRANCISCO, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today will present preclinical

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
17 May, 2022 FinancialContent

Gainers Allogene Therapeutics (NASDAQ:ALLO) shares increased by 12.7% to $7.98 during Tuesday's pre-market session. ...

Allogene Therapeutics, Inc (ALLO) is a NASDAQ Common Stock listed in , ,

970x250